FY2025 EPS Estimates for GPCR Decreased by Cantor Fitzgerald

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Free Report) - Research analysts at Cantor Fitzgerald decreased their FY2025 earnings per share (EPS) estimates for Structure Therapeutics in a report issued on Thursday, August 7th. Cantor Fitzgerald analyst P. Agrawal now forecasts that the company will post earnings of ($1.50) per share for the year, down from their prior estimate of ($1.09). Cantor Fitzgerald has a "Overweight" rating and a $65.00 price objective on the stock. The consensus estimate for Structure Therapeutics' current full-year earnings is ($0.82) per share. Cantor Fitzgerald also issued estimates for Structure Therapeutics' FY2026 earnings at ($2.11) EPS.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last issued its earnings results on Wednesday, August 6th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by ($0.08).

Other equities analysts have also recently issued research reports about the company. JMP Securities decreased their price objective on Structure Therapeutics from $89.00 to $87.00 and set a "market outperform" rating for the company in a research note on Thursday, August 7th. HC Wainwright dropped their target price on Structure Therapeutics from $75.00 to $60.00 and set a "buy" rating on the stock in a report on Thursday, August 7th. Guggenheim dropped their target price on Structure Therapeutics from $92.00 to $90.00 and set a "buy" rating on the stock in a report on Thursday, August 7th. Finally, Citigroup assumed coverage on Structure Therapeutics in a report on Friday, May 2nd. They set a "buy" rating and a $60.00 price objective on the stock. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Structure Therapeutics presently has an average rating of "Buy" and an average target price of $75.71.

Structure Therapeutics Trading Down 2.0%

Structure Therapeutics stock traded down $0.39 during midday trading on Monday, reaching $18.77. 256,625 shares of the stock traded hands, compared to its average volume of 876,652. The company has a 50-day simple moving average of $19.58 and a two-hundred day simple moving average of $21.65. Structure Therapeutics has a 12-month low of $13.22 and a 12-month high of $45.37. The firm has a market cap of $1.08 billion, a PE ratio of -17.94 and a beta of -1.89.

Institutional Trading of Structure Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. GF Fund Management CO. LTD. acquired a new stake in Structure Therapeutics during the fourth quarter worth about $34,000. National Bank of Canada FI grew its stake in Structure Therapeutics by 1,448.2% during the 1st quarter. National Bank of Canada FI now owns 2,957 shares of the company's stock valued at $51,000 after purchasing an additional 2,766 shares in the last quarter. Assetmark Inc. grew its stake in Structure Therapeutics by 39.9% during the 2nd quarter. Assetmark Inc. now owns 2,877 shares of the company's stock valued at $60,000 after purchasing an additional 820 shares in the last quarter. Virtus ETF Advisers LLC grew its position in shares of Structure Therapeutics by 25.5% in the 4th quarter. Virtus ETF Advisers LLC now owns 2,242 shares of the company's stock worth $61,000 after acquiring an additional 455 shares in the last quarter. Finally, ANTIPODES PARTNERS Ltd grew its position in shares of Structure Therapeutics by 310.7% in the 1st quarter. ANTIPODES PARTNERS Ltd now owns 4,247 shares of the company's stock worth $74,000 after acquiring an additional 3,213 shares in the last quarter. 91.78% of the stock is currently owned by hedge funds and other institutional investors.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.